Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: Comparison with an MTP inhibitor

European Journal of Pharmacology

Volumn 455, Issue 2-3, 2002, Pages 161-167

  Funatsu, Toshiyuki ^a   Kakuta, Hirotoshi ^a   Takasu, Toshiyuki ^a   Miyata, Keiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

(Rat); Atorvastatin; Beta oxidation; BMS 201038; Triglyceride

Indexed keywords

ATORVASTATIN; BMS 201038; CHOLESTEROL ESTER; FATTY ACID; PROTEIN INHIBITOR; SUCROSE; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN B; BENZIMIDAZOLE DERIVATIVE; BMS201038; CARRIER PROTEIN; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PYRROLE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; HYPERTRIGLYCERIDEMIA; LIPID LIVER LEVEL; LIVER; LIVER LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SUGAR INTAKE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; LIPID METABOLISM; MALE; METABOLISM; OXIDATION REDUCTION REACTION; SECRETION; SPRAGUE DAWLEY RAT;

ANIMALS; APOLIPOPROTEINS B; BENZIMIDAZOLES; CARRIER PROTEINS; CHOLESTEROL; FATTY ACIDS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPOPROTEINS, VLDL; LIVER; MALE; OXIDATION-REDUCTION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SUCROSE; TRIGLYCERIDES;

EID: 0037195602     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02611-0     Document Type: Article

References (31)

1. Agius L., Peak M., Sherratt S.A. Differences between human, rat and guinea pig hepatocyte cultures. A comparative study of their rates of beta-oxidation and esterification of palmitate and their sensitivity to R-etomoxir. Biochem. Pharmacol. 42:1991;1711-1715.
2. Aguilar-Salinas C.A., Barrett H., Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis. 141:1998;203-207.
3. Bagdade J.D., Yee E., Albers J., Pykalisto O.J. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat. Metab. Clin. Exp. 25:1976;533-542.
4. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
5. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H., Newton R.S., Huff M.W. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology. 140:1999;5293-5302.
6. Carr T.P., Andresen C.J., Rudel-L L. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 26:1993;39-42.
7. Carrella M., Fong L.G., Loguercio C., Del Piano C. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver. Metab. Clin. Exp. 48:1999;618-626.
8. Chance D.S., Wu S.M., McIntosh M.K. Inverse relationship between peroxisomal and mitochondrial beta-oxidation in HepG2 cells treated with dehydroepiandrosterone and clofibric acid. Proc. Soc. Exp. Biol. Med. 208:1995;378-384.
9. East C., Bilheimer D.W., Grundy S.M. Combination drug therapy for familial combined hyperlipidemia. Ann. Intern. Med. 109:1988;25-32.
10. Folch J., Lees M., Sloane-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:1957;497-509.
11. Fujioka T., Tsujita Y., Shimotsu H. Induction of fatty acid synthesis by pravastatin sodium in rat liver and primary hepatocytes. Eur. J. Pharmacol. 328:1997;235-239.
12. Funatsu T., Suzuki K., Goto M., Arai Y., Kakuta H., Tanaka H., Yasuda S., Ida M., Nishijima S., Miyata K. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 157:2001;107-115.
13. Funatsu T., Goto M., Kakuta H., Suzuki M., Ida M., Nishijima S., Tanaka H., Yasuda S., Miyata K. Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. Biochim. Biophys. Acta. 1580:2002;161-170.
14. Goldstein J.L., Basu S.K., Brown M.S. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98:1983;241-260.
15. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N. Engl. J. Med. 321:1989;1311-1315.
16. Gregg R.E., Wetterau J.R. The molecular basis of abetalipoproteinemia. Curr. Opin. Lipidol. 5:1994;81-86.
17. Guzman M., Cortes J.P., Castro J. Effects of lovastatin on hepatic fatty acid metabolism. Lipids. 28:1993;1087-1093.
18. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 3:1996;213-219.
19. Ide T., Ontko J.A. Increased secretion of very low density lipoprotein triglyceride following inhibition of long chain fatty acid oxidation in isolated rat liver. J. Biol. Chem. 256:1981;10247-10255.
20. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. (the CURVES study) Am. J. Cardiol. 81:1998;582-587.
21. Latruffe N., Malki M.C., Nicolas-Frances V., Clemencet M.C., Jannin B., Berlot J.P. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases. Biochem. Pharmacol. 60:2000;1027-1032.
22. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., Najib-Fruchart J., Glineur C., Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 107:2001;1423-1432.
23. Mohammadi A., Macri J., Newton R., Romain T., Dulay D., Adeli K. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 18:1998;783-793.
24. Muoio D.M., Seefeld K., Witters L.A., Coleman R.A. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem. J. 338:1999;783-791.
25. Sato A., Watanabe K., Fukuzumi H., Hase K., Ishida F., Kamei T. Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats. Biochem. Pharmacol. 41:1991;1163-1172.
26. Stein D.T., Devaraj S., Balis D., Adams-Huet B., Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 21:2001;2026-2031.
27. Strobl W., Gorder N.L., Fienup G.A., Lin-Lee Y.C., Gotto A.M. Jr., Patsch W. Effect of sucrose diet on apolipoprotein biosynthesis in rat liver. Increase in apolipoprotein E gene transcription. J. Biol. Chem. 264:1989;1190-1194.
28. Wetterau J.R., Zilversmit D.B. Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues. Biochim. Biophys. Acta. 875:1986;610-617.
29. Wetterau J.R., Gregg R.E., Harrity T.W., Arbeeny C., Cap M., Connolly F., Chu C.H., George R.J., Gordon D.A., Jamil H., Jolibois K.G., Kunselman L.K., Lan S.J., Maccagnan T.J., Ricci B., Yan M., Young D., Chen Y., Fryszman O.M., Logan J.V., Musial C.L., Poss M.A., Robl J.A., Simpkins L.M., Slusarchyk W.A., Sulsky R., Taunk P., Magnin D.R., Tino J.A., Lawrence R.M., Dickson J.K. Jr., Biller S.A. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 282:1998;751-754.
30. Yamada N., Havel R.J. Measurement of apolipoprotein B radioactivity in whole blood plasma by precipitation with isopropanol. J. Lipid Res. 27:1986;910-912.
31. Yamamoto K., Todaka N., Goto H., Jayasooriya A.P., Sakono M., Ogawa Y., Fukuda N. Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver. Life Sci. 65:1999;1493-1502.